Baxter International Financial Model
Medical Devices Company Financials Example (Free Excel Download)
Baxter International Inc. is a global medical technology company that develops and manufactures products for hospitals, clinics, and homes.
professionals from Deloitte
Used by professionals from
About this model
This model provides a sum-of-the-parts equity valuation and cash flow forecasting tool for an analyst assessing Baxter International's standalone earnings power and deleveraging trajectory following the January 2025 divestiture of its Kidney Care business (Vantive).
Baxter International Inc. is a global medical technology company that develops and manufactures products for hospitals, clinics, and homes. Following recent divestitures, the company operates a streamlined portfolio focused on critical care, surgical products, and patient monitoring.
The business is divided into three continuing segments: Medical Products & Therapies (approximately 45% of continuing revenue), Healthcare Systems & Technologies (approximately 40%), and Pharmaceuticals (approximately 15%). The company has a significant global footprint, with international sales comprising roughly 45% of total revenue. Baxter operates a hybrid business model, combining asset-heavy sterile manufacturing for its IV and pharmaceutical products with higher-margin, technology-driven capital equipment and connected care solutions acquired via the 2021 Hillrom transaction. Its competitive position is strong, often holding top-two market share in IV solutions, smart beds, and inhaled anaesthetics. Recent major events include the transformational acquisition of Hillrom (2021), the divestiture of BioPharma Solutions (2023), and the sale of its Kidney Care segment (Vantive) to Carlyle in January 2025, which fundamentally altered its reporting structure and capital structure.
The downloadable Baxter International financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsBaxter International financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $12.15B | $10.06B | $10.36B | $10.64B | $11.24B |
| Gross profit | $4.72B | $3.55B | $4.15B | $3.98B | $3.38B |
| Operating income | $1.35B | -$2.85B | $707.0M | $14.0M | -$308.0M |
| Net income | $1.28B | -$2.43B | $2.66B | -$649.0M | -$957.0M |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Baxter International
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Medical Products & Therapies (MPT)
- Segment name: Medical Products & Therapies
- Revenue driver formula: IV Volume x Average Selling Price + Advanced Surgery Volume x Price
- Historical growth rate: 2% to 4% operational CAGR
- Key growth levers and headwinds: Growth is driven by surgical procedure volumes and demand for hemostats and sealants. Headwinds include ongoing IV push utilisation trends (shifting away from traditional IV bags) and the recent exit from the IV solutions market in China.
- Pricing dynamics: Largely contractual with group purchasing organisations (GPOs) and hospital networks; subject to inflationary pricing adjustments where contracts permit.
- Revenue recognition notes: Recognised at a point in time upon delivery of consumable products.
- Seasonality: Q4 is typically the strongest quarter due to hospital budget flush and elective surgery seasonality.
Healthcare Systems & Technologies (HST)
- Segment name: Healthcare Systems & Technologies
- Revenue driver formula: Capital Equipment Placements x Unit Price + Software/Service Recurring Revenue
- Historical growth rate: 3% to 5% operational CAGR
- Key growth levers and headwinds: Driven by hospital capital expenditure cycles, upgrades to smart bed systems (e.g., Progressa+ ICU beds), and adoption of Care & Connectivity Solutions. Headwinds include hospital budget constraints and extended capital equipment replacement cycles.
- Pricing dynamics: High-ticket capital sales negotiated via long-term hospital network contracts, supplemented by higher-margin, sticky software and maintenance contracts.
- Revenue recognition notes: Equipment recognised upon installation and acceptance; software and maintenance recognised rateably over the contract term.
- Seasonality: Highly seasonal, with Q4 historically accounting for the largest share of capital equipment orders.
Pharmaceuticals
- Segment name: Pharmaceuticals
- Revenue driver formula: Vials/Doses Sold x Price per Unit
- Historical growth rate: 1% to 3% operational CAGR
- Key growth levers and headwinds: Driven by demand for specialty injectable pharmaceuticals and inhaled anaesthetics. Headwinds include generic competition, price erosion, and intermittent supply chain challenges.
- Pricing dynamics: Highly competitive, spot and contract pricing, heavily influenced by generic market entrants and drug shortages.
- Revenue recognition notes: Point in time upon delivery.
- Seasonality: Relatively stable throughout the year, though respiratory products can spike during severe winter flu seasons.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Raw materials (resins, plastics, active pharmaceutical ingredients), direct manufacturing labour, global freight and logistics, manufacturing overhead, and tariffs.
- Gross margin range: 35% to 37% on an adjusted basis for continuing operations (compressed to roughly 35.5% in late 2025).
- Key input costs and commodity exposures: Highly exposed to petroleum-based plastics, electronic components for HST, and global shipping rates. Tariffs represent a material headwind (estimated at $80 million for 2026).
- How COGS scales with revenue: High fixed-cost manufacturing footprint means gross margins are highly sensitive to volume throughput and manufacturing variances.
Operating Expenses
- R&D: Typically runs at 3.8% to 4.2% of sales. It covers clinical trials, software development for connected care, and product engineering.
- SG&A: Typically 21% to 22% of sales. Driven by a large global direct sales force, marketing, and corporate overhead. Includes stranded costs post-Vantive separation that are actively being restructured.
- Depreciation & Amortisation: Significant intangible amortisation (historically over $1 billion annually) stemming from the Hillrom acquisition. Tangible depreciation is tied to the heavy manufacturing base.
- Stock-Based Compensation: Approximately 1% to 1.5% of revenue.
- Restructuring / one-time charges: Frequent and highly material. The company has incurred billions in special items recently, including goodwill impairments, separation costs for Vantive, and business optimisation charges.
Margin Profile
- Gross margin: 35% to 37% (adjusted).
- EBITDA margin: 18% to 20% (adjusted).
- Operating margin: 13% to 14% (adjusted continuing operations).
- Net margin: 8% to 10% (adjusted continuing operations).
- Margin trend: Compressing recently due to manufacturing variances, tariffs, and stranded overhead post-spinoff, though management is targeting expansion via cost-saving initiatives. Segment margins vary widely (MPT at roughly 15%, Pharma lagging at roughly 6%).
Balance Sheet Structure
- Total assets: Approximately $25 billion to $30 billion (post-Vantive sale).
- Key asset categories: Intangible assets and goodwill dominate the asset base due to the Hillrom acquisition. PP&E is also substantial due to the global manufacturing network.
- Goodwill & intangibles as % of total assets: Historically 50% to 60%, reflecting a highly acquisitive past.
- Working capital profile:
- Days Sales Outstanding (DSO): 45 to 55 days.
- Days Inventory Outstanding (DIO): 85 to 95 days (high inventory needed to prevent drug/IV shortages).
- Days Payable Outstanding (DPO): 40 to 50 days.
- Net working capital as % of revenue: 15% to 20%.
- Is working capital positive or negative? Positive. The company consumes cash to build inventory ahead of product launches or during supply chain disruptions.
- PP&E: Consists of global sterile manufacturing facilities, warehouses, and testing labs. Maintenance capex is a significant requirement.
- Right-of-use assets / operating leases: Material but manageable, primarily related to regional office space and distribution centres.
Capital Expenditure & Investment
- Capex as % of revenue: 4% to 5%.
- Maintenance capex vs. growth capex: Approximately 60% maintenance (facility upgrades, quality control systems) and 40% growth (new production lines, automation).
- Major capex programmes underway or planned: Upgrading legacy IV manufacturing facilities and expanding capacity for advanced surgery products.
- Capitalised software / development costs: Moderate, primarily within the HST segment for Care & Connectivity Solutions.
- M&A pattern: Historically a transformational acquirer (Hillrom for $12.5 billion), but currently focused on organic growth, deleveraging, and portfolio rationalisation (selling BPS and Vantive).
- Typical acquisition multiple paid: 15x to 18x EV/EBITDA for high-quality medtech assets.
Debt & Capital Structure
- Total debt: Significantly reduced in Q1 2025 using the multi-billion dollar proceeds from the Vantive sale to Carlyle.
- Debt/EBITDA ratio: Targeting 2.5x to 3.0x following the Vantive debt paydown.
- Credit rating: Investment grade (typically BBB/Baa2 range).
- Key debt instruments: Senior unsecured notes (bonds) of varying maturities, commercial paper programme, and a revolving credit facility.
- Maturity profile: Well-laddered, though the company actively retired near-term maturities with Vantive proceeds.
- Interest rate profile: Predominantly fixed-rate bonds, with a weighted average cost of debt around 3.5% to 4.5%.
- Covenants: Standard interest coverage and leverage ratio covenants on the revolving credit facility.
- Share repurchase programme: Historically active, but paused or minimised recently to prioritise debt reduction.
- Dividend policy: Regular quarterly cash dividend (historically around $0.29 per share quarterly), yielding approximately 2.5% to 3.0%.
Cash Flow Characteristics
- Operating cash flow conversion: Adjusted Net Income to OCF is typically 1.0x to 1.2x, though GAAP conversion is skewed by massive non-cash impairment charges.
- Free cash flow margin: 10% to 12% of sales on a normalised basis.
- Major non-cash items: Intangible amortisation, depreciation, stock-based compensation, and frequent goodwill impairment charges.
- Working capital cash flow impact: Inventory builds have been a use of cash in recent years to buffer against supply chain shocks.
- Capex intensity: Moderate (4% to 5% of sales), requiring consistent reinvestment to meet FDA and global regulatory manufacturing standards.
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are often lower than the GAAP statutory rate due to R&D tax credits, foreign earnings mix, and deductibility of certain restructuring costs. Adjusted effective tax rate is typically 16% to 18%.
Sheet Structure
- Assumptions: Hardcoded drivers for macroeconomic inputs, segment growth rates, margin targets, working capital days, and tax rates.
- Scenarios: Toggle for Base, Bull, and Bear cases driving the Assumptions sheet.
- Income Statement: Consolidated P&L from Revenue down to Net Income and EPS. Must separate Continuing Operations from Discontinued Operations (Vantive).
- Revenue Build: Segment-level detail forecasting Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
- Cost Build: Detailed breakdown of COGS (including tariff impacts), SG&A, R&D, and special items.
- Balance Sheet: Standard assets, liabilities, and equity. Must reflect the Q1 2025 removal of Vantive assets/liabilities and the corresponding cash/debt paydown.
- Cash Flow Statement: OCF, CFI, CFF, and the bridge from GAAP Net Income.
- Working Capital: Schedules for Accounts Receivable, Inventory, and Accounts Payable driven by DSO, DIO, and DPO.
- Depreciation & Amortisation: Waterfall schedule for tangible capex and legacy Hillrom intangible amortisation.
- Debt Schedule: Tranche-by-tranche bond schedule, commercial paper, interest expense calculation, and mandatory paydowns.
- Adjusted Earnings Reconciliation: Crucial sheet bridging GAAP EPS to Adjusted EPS by adding back amortisation, restructuring, and impairments.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, terminal value, and implied share price.
Key Financial Relationships
- `MPT Revenue = Prior Year MPT Revenue * (1 + MPT Volume Growth + MPT Price/Mix)`
- `HST Revenue = Prior Year HST Revenue * (1 + HST Capital Placements Growth + HST Recurring Revenue Growth)`
- `Pharmaceuticals Revenue = Prior Year Pharma Revenue * (1 + Pharma Volume Growth + Pharma Price Erosion)`
- `Total Net Sales = MPT Revenue + HST Revenue + Pharmaceuticals Revenue + Other Sales`
- `COGS = (Total Net Sales * Base COGS %) + Tariff Headwinds ($80M in 2026)`
- `Adjusted Gross Profit = Total Net Sales - COGS (excluding special manufacturing variances)`
- `R&D Expense = Total Net Sales * R&D Margin (historically ~3.9%)`
- `SG&A Expense = Total Net Sales * SG&A Margin (historically ~21.4%)`
- `Adjusted Operating Income = Adjusted Gross Profit - R&D Expense - SG&A Expense + TSA Income`
- `Interest Expense = Average Total Debt * Weighted Average Interest Rate`
- `Adjusted Net Income = (Adjusted Operating Income - Interest Expense) * (1 - Adjusted Effective Tax Rate)`
- `Free Cash Flow = Operating Cash Flow - Capital Expenditures`
Cross-Sheet Dependencies
- The Revenue Build feeds the top line of the Income Statement and drives the Working Capital sheet (Accounts Receivable).
- The Cost Build feeds COGS and Opex on the Income Statement and drives Inventory and Accounts Payable on the Working Capital sheet.
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement.
- The Cash Flow Statement calculates the net change in cash, which feeds the Cash line on the Balance Sheet.
- The Debt Schedule requires operating cash flow from the Cash Flow Statement to determine cash available for debt paydown.
- Circularity Risk: The Debt Schedule calculates Interest Expense, which feeds the Income Statement, which changes Net Income, which changes Operating Cash Flow, which changes the cash available for debt paydown on the Debt Schedule. A circuit breaker toggle must be included.
Sign Convention
- Revenues, asset balances, liability balances, and equity balances are entered and displayed as positive numbers.
- Expenses on the Income Statement (COGS, SG&A, R&D, Interest Expense, Taxes) are entered as positive numbers and explicitly subtracted in subtotal formulas (e.g., `Gross Profit = Revenue - COGS`).
- On the Cash Flow Statement, cash inflows are positive and cash outflows (e.g., Capital Expenditures, Debt Repayments, Dividends Paid) are negative.
- Working capital changes on the Cash Flow Statement: an increase in an asset is negative; an increase in a liability is positive.
Things Most Likely to Go Wrong
- Including Vantive in forward estimates: The Kidney Care business was sold in January 2025. The model must strictly exclude Vantive from 2025 and 2026 continuing operations revenue and operating income.
- Ignoring TSA Income: Baxter receives Transition Services Agreement (TSA) income from Vantive (estimated at $130M to $140M in 2026). Excluding this will artificially depress near-term operating margins.
- Mismodelling Intangible Amortisation: GAAP earnings are heavily penalised by Hillrom amortisation. Valuation must be based on Adjusted EPS, which adds this back.
- Tariff Impacts: The model must account for the specific $80 million tariff headwind guided for 2026 within COGS.
- Debt Paydown Timing: The model must reflect a massive step-down in the debt balance in Q1 2025 using the Vantive sale proceeds; using 2024 year-end debt for forward interest calculations will drastically overstate interest expense.
- Stranded Costs: Post-spinoff, Baxter retains some corporate overhead previously allocated to Vantive. SG&A margins will initially look inflated until cost-saving programmes take effect.
- China IV Exit: Historical MPT growth rates include China IV sales. The model must step down the MPT revenue base to account for this market exit.
- GAAP vs. Adjusted Tax Rate: Using the GAAP tax rate will yield erratic results due to special items. The model must use the management-guided adjusted effective tax rate.
Validation Checks
- "Adjusted Gross Margin should be in the 35.0% to 36.5% range; flag if outside this band."
- "Adjusted Operating Margin should be in the 13.0% to 14.5% range for 2026; flag if outside."
- "R&D as a % of sales should remain between 3.8% and 4.2%."
- "Total Net Sales growth for continuing operations should not exceed 5% without flagging (management guidance is 1% to 2% operational for 2026)."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Interest expense in 2025/2026 must be significantly lower than 2024 due to the Vantive proceeds debt paydown."
- "Capex as a % of revenue should run between 4.0% and 5.0%."
- "Dividend payout ratio should be checked against the historical $0.29 quarterly per share rate."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| MPT Revenue Growth | 2.5 | % | Midpoint of historical operational growth, adjusting for China IV exit |
| HST Revenue Growth | 3.5 | % | Steady capital replacement cycle and software growth |
| Pharmaceuticals Revenue Growth | 1.5 | % | Low growth due to generic price erosion and supply constraints |
| Adjusted Gross Margin | 35.5 | % | Based on Q4 2025 actuals and 2026 guidance including tariff impacts |
| SG&A as % of Revenue | 21.4 | % | Based on Q4 2025 actuals, reflecting stranded costs post-spinoff |
| R&D as % of Revenue | 3.9 | % | Based on Q4 2025 actuals and historical averages |
| TSA Income (2026) | 135 | $ Millions | Midpoint of management guidance ($130M - $140M) |
| Tariff Headwind (2026) | 80 | $ Millions | Management guidance for 2026 |
| Adjusted Effective Tax Rate | 17.0 | % | Historical adjusted average |
| Capex as % of Revenue | 4.5 | % | Historical average required to maintain global manufacturing |
| Days Sales Outstanding (DSO) | 50 | Days | Calculated from recent balance sheets |
| Days Inventory Outstanding (DIO) | 90 | Days | Calculated from recent balance sheets |
| Days Payable Outstanding (DPO) | 45 | Days | Calculated from recent balance sheets |
| Weighted Average Cost of Debt | 4.0 | % | Estimated based on current bond ladder |
| Quarterly Dividend per Share | 0.29 | $ | Maintained historical dividend rate |
| WACC | 8.0 | % | Standard medtech discount rate |
| Terminal Growth Rate | 2.0 | % | Long-term GDP and healthcare spending growth |
Data Sources & Benchmarks
- Filings: SEC EDGAR (Baxter International Inc. 10-K, 10-Q, 8-K).
- Presentations: Baxter Investor Relations website (Q4 2025 Earnings Presentation, Vantive Separation updates).
- Key Peers: Medtronic (MDT), Becton Dickinson (BDX), Stryker (SYK), Abbott Laboratories (ABT).
- Industry Data: IQVIA for pharmaceutical volume and pricing trends; American Hospital Association (AHA) for hospital capital expenditure budgets.
- Consensus Estimates: FactSet or Bloomberg for forward revenue and Adjusted EPS consensus.
Sources
- Baxter International Inc. Q4 2025 and Full-Year 2025 Earnings Release and Presentation (February 2026).
- Baxter International Inc. 2025 Form 10-K filed with the SEC.
- Vantive Spinoff Announcements and Carlyle Acquisition Press Releases (January 2025).
- Baxter Investor Relations Transcripts (Q4 2025 Earnings Call).
Do more with the Baxter International model
Frequently asked
What is Baxter International's core business focus after recent divestitures?+
Following recent divestitures, Baxter International is a global medical technology company focused on critical care, surgical products, and patient monitoring. Its portfolio includes Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals segments.
What are the primary revenue segments for Baxter International?+
Baxter International's continuing revenue is primarily driven by its Medical Products & Therapies segment (approximately 45%), Healthcare Systems & Technologies (approximately 40%), and Pharmaceuticals (approximately 15%). The company also generates significant international sales, comprising roughly 45% of total revenue.
What is the assumed revenue growth rate in the Baxter International financial model?+
The financial model for Baxter International incorporates a revenue growth assumption of approximately -2.28%. This figure is a critical input for projecting the company's future financial performance over the forecast horizon.
What is Baxter International's typical capital expenditure as a percentage of revenue?+
Baxter International typically allocates 4% to 5% of its revenue to capital expenditures. Approximately 60% of this is for maintenance, while 40% is for growth initiatives like upgrading IV manufacturing and expanding advanced surgery product capacity.
What is the main purpose of the Baxter International financial model?+
The Baxter International financial model serves as a sum-of-the-parts equity valuation and cash flow forecasting tool. It enables analysts to assess the company's standalone earnings power and its deleveraging trajectory after the Kidney Care business divestiture.
Can I access a downloadable financial model for Baxter International?+
Yes, an Excel financial model for Baxter International is available for download. This general corporate model provides a forecast horizon from FY2026 through FY2030.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Medical Devices Company Financial Models
Browse another company in the same sector.
Abbott Laboratories
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad line of healthcare products.
Align Technology
Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry.
Becton Dickinson
Becton, Dickinson and Company (BD) is a leading global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products.
Boston Scientific
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties.
Cooper Companies
The Cooper Companies, Inc.
Dexcom
Dexcom is a medical device company focused on the design, development, and commercialisation of continuous glucose monitoring systems that provide real-time glucose readings for people with diabetes, replacing traditional fingerstick testing.
Edwards Lifesciences
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease.
GE HealthCare
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator that provides integrated equipment, services, and data analytics to hospitals and clinicians.
Explore more Healthcare financial model templates.
